Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Carbylan Therapeutics
Palo Alto, California, United Statescarbylan.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Carbylan’s lead program was Hydros‑TA—a proprietary intra-articular injectable combining hyaluronic acid and triamcinolone acetonide—developed for pain associated with osteoarthritis of the knee. The company completed a pivotal Phase 3 trial (COR1.1) but suspended further clinical development in April 2016 following disappointing results.[9][6] Subsequently, Carbylan merged with KalVista Pharmaceuticals in late 2016 and ceased independent operations.[1][10]
- Therapeutic areas
- Rheumatology
- Modalities
- Combination drug/device productsIntra-articular injectablesSmall molecules (historically; post-merger focus shifted to small molecule protease inhibitors under KalVista)[2][1]
- Industry
- Biotech
Beyond the preview
Go deeper on Carbylan Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carbylan Therapeutics.